The RNA targeting small molecules therapeutics market is estimated to be worth USD 8.3 billion in 2030.

 

In recent years, RNA’s potential as a target molecule for small molecules has been widely recognized; a number of players have developed proprietary technologies for direct and indirect RNA targeting, to treat a wide range of clinical conditions

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “RNA Targeting Small Molecules Therapeutics Market”

 

The report features an extensive study of the current market landscape and future potential of the players engaged in the discovery and development of RNA targeting small molecules therapeutics. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

 

§  An in-depth review of the market landscape of players that are engaged in the discovery and development of RNA targeting small molecules therapeutics being evaluated at both preclinical and clinical stages of development. It also includes a detailed landscape of developers active in this domain.

§  An insightful analysis of the company competitiveness and investment landscape comparing the key players engaged in the domain of RNA targeting small molecules. Further, it includes start-ups and investment activity across different players.

§  An analysis of the partnerships that have been inked by stakeholders in this area, during the period between 2017 and 2021.

§  An in-depth analysis of investments made, during the period between 2015 and 2021, in companies that are engaged in the development of RNA targeting small molecules therapeutics.

§  Elaborate profiles of key players engaged in the development of RNA targeting small molecules therapeutics.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

 

§  Type of Target Disease Indication 

§  Aniridia

§  Breast Cancer

§  Castrate-resistant Prostate Cancer

§  Colorectal Cancer

§  Cystic Fibrosis

§  Crohn’s Disease

§  Duchenne Muscular Dystrophy

§  Dravet Syndrome

§  HIV Infections

§  Impaired Renal Function

§  NSCLC

§  Rheumatoid Arthritis

§  Spinal Muscular Atrophy

§  Ulcerative Colitis

 

§  Type of Therapeutic Area

§   Autoimmune Disorders

§   Genetic Disorders

§   Inflammatory Disorders

§   Infectious Disorders

§   Kidney Disorders

§   Neurological Disorders

§   Oncological Disorders

§   Ophthalmic Disorders

§   Rare Disorders

§   Respiratory Disorders

 

§  Type of Target Molecule

§  CDKL5

§  Cap Binding Complex

§  Dystrophin Protein

§  Estrogen Receptor Alpha

§  G542X

§  MNK1 / MNK2

§  PAX6 Gene

§  SMN2

 

§  Type of Approach

§  Indirect RNA Targeting- Epitranscriptomics

§  mRNA Translation Modulation

§  RNA Splicing Modification

 

§  Route of Administration

§  Oral

§  Subcutaneous

 

§  Key Geographical Regions

§  North America                         

§  Europe

 

Transcripts of interviews held with the following senior level representatives of stakeholder companies

§  Clara Assouline (Business Development, Anima Biotech)

§  Dominique Cheneval (Co-Founder and Chief Executive Officer, Novation Pharmaceuticals)

 

Key companies covered in the report

§  Abivax

§  AC Immune

§  Arrakis Therapeutics

§  eFFECTOR Therapeutics

§  ELOXX Pharmaceuticals

§  PTC Therapeutics

§  H3 Biomedicine

§  Ribometrix

§  Skyhawk Therapeutics

§  STORM Therapeutics

 

For more information, please click on the following link

https://www.rootsanalysis.com/reports/rna-targeting-small-molecule-therapeutics-market.html

 

Other Recent Offerings

1.     RAS Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

2.     DNA Damage Response Targeting Therapeutics: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

3.     HER2 Targeting Therapies: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

 

Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

Comments

Post a Comment

Popular posts from this blog

Patient Recruitment and Retention Services, 2019-2030

  To order this detailed 300+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/patient-recruitment-and-retention-services-market-2019-2030/245.html   Key Inclusions §   A detailed assessment of the current market landscape, including information on drug developer(s), §   A detailed assessment of the current market landscape of companies offering patient recruitment and retention services, including information on over 10 types of patient outreach methods employed, types of services offered ([A] patient recruitment (including pre-screening and Institutional Review Board (IRB) / Ethics Committee (EC) submission), [B] patient retention (considering various strategies, such as the use of study-branded gifts, study-branded reminders, providing education and support materials, reimbursement programs, transportation programs, patient engagement web site, patient reconnect programs, mobile applications to track patient engagement...
Read more

Targeted protein degradation enabling technologies market

  Targeted protein degradation (TPD) is considered to be a transformative approach to selectively eliminate disease-causing proteins; over time, this upcoming class of small molecules has generated significant enthusiasm within the medical community   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Targeted Protein Degradation Market, 2021-2030 . ”   The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape of drug developers engaged in the development of targeted protein degradation-based therapeutics.  §   An overview of the overall landscape of target protein degradation enabling te...
Read more